Drug offers prevention hope for women with BRCA breast cancer gene

August 6, 2013 by Sunanda Creagh, The Conversation
Tamoxifen may offer hope for women with a gene mutation that puts them at a high risk of developing breast cancer. Credit: Paloma León y Luismi Cavallé

Use of the anti-cancer drug Tamoxifen is associated with a dramatically reduced risk of developing a second breast tumour among women with a high risk gene mutation who have experienced breast cancer already, a new study has found.

Tamoxifen blocks the and is already used to prevent . Until now, however, it was not routinely taken by with the gene mutations BRCA 1 and BRCA 2, which put them in the highest risk category for breast cancer.

Actress Angelina Jolie recently had a after discovering she carried the gene mutation BRCA1.

The new study, published today in the Journal of Clinical Oncology, analysed data on 2,464 women from Europe, North America and Australia who carried the BRCA1 or BRCA2 mutations.

The researchers found that taking Tamoxifen was associated with a reduced risk of developing a second cancer among women with the gene mutations.

"We have known for a few years that Tamoxifen is effective for preventing breast cancer in women who are at somewhat increased risk but there's always been considerable controversy about whether that was also true for women at the highest risk, that is, women who carry BRCA 1 or BRCA2 gene mutation," said lead author Professor Kelly-Anne Phillips from the University of Melbourne and Melbourne's Peter MacCallum Cancer Centre

"This study shows Tamoxifen may be effective in that important sub group as well."

Professor Phillips said although Tamoxifen is less effective than surgery, the findings provided another choice for women who wanted to avoid surgical options.

"The take home message is these women should go back to their specialists and talk through their risk management options."

This research was supported by funding from Cancer Australia, the National Breast Cancer Foundation.

Prevention strategy

Professor Geoff Lindeman from the Breast Cancer Laboratory at Walter and Eliza Hall Institute, said it was an important finding that showed that Tamoxifen may offer a possible prevention strategy for women with BRCA1 and BRCA2.

"Historically, the uptake of this drug has not been great for high risk women who are looking for ways to prevent breast cancer," he said.

"This is partly due to the fear of potential side effects which can include cancer of the womb or blood clots. However, for younger women the risk of cancer of the womb is not great and the risk of clots is about the same as for women who take the pill. Tamoxifen can also cause hot flushes," said Professor Lindeman, who was not involved in the study.

"This study provides new information in an area where we haven't had much data to go on. It should increase the confidence that Tamoxifen may offer an additional strategy to help prevent breast cancer for BRCA mutation carriers."

Ian Olver, Clinical Professor of Oncology at Cancer Council Australia, said the finding was based on a large study "that showed a reduction in risk for those carriers in the contralateral breast".

Explore further: Women at high breast cancer risk should consider preventive drugs: experts

Related Stories

Women at high breast cancer risk should consider preventive drugs: experts

July 9, 2013
(HealthDay)—Women at high risk of breast cancer should discuss with their doctors the use of so-called chemopreventive drugs to reduce that risk, according to a new practice guideline issued by the American Society of Clinical ...

UK doctors urged to use preventative breast cancer drugs

June 25, 2013
Hundreds of thousands of women at high risk of developing breast cancer in Britain should be given drugs which could dramatically reduce their chances of getting the disease, doctors were advised Tuesday.

Polygenic risk score helpful for women with familial breast CA

December 18, 2012
(HealthDay)—For women affected by familial breast cancer, a polygenic risk score based on 22 genomic variants can identify women at high-risk of breast cancer, according to a study published in the Dec. 10 issue of the ...

What is BRCA1?

May 15, 2013
Actress Angelina Jolie has today written an op-ed in the New York Times explaining that she has opted to have a double mastectomy because she carries the hereditary BRCA1 gene, which she says increases her risk of breast ...

Study confirms long term benefits of tamoxifen

June 3, 2013
(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference.

Newly identified markers may predict who will respond to breast cancer prevention therapy

June 13, 2013
Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, ...

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.